Prostate cancer and homologous recombination repair gene mutations: a monocentric observational study on clinical and histopathological features and their association with oncological outcomes
Fuente:
Zenodo
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2025
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901132333285376 |
|---|---|
| author | Rossetti, Sabrina Coppola, Elisabetta |
| author_facet | Rossetti, Sabrina Coppola, Elisabetta |
| contents | <p><span lang="EN-US">This study provides real-world evidence that homologous recombination repair (HRR) gene mutations, particularly in <em>BRCA2</em>, are associated with more aggressive clinical and pathological features in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Importantly, mutations located in functional domains of <em>BRCA2</em>, such as the DNA-binding domain and exon 11, were linked to worse oncological outcomes. The findings suggest that not all <em>BRCA2</em> mutations carry the same prognostic value. These results support the potential utility of detailed genetic profiling for risk stratification and treatment personalization in mHSPC.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15189983 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Prostate cancer and homologous recombination repair gene mutations: a monocentric observational study on clinical and histopathological features and their association with oncological outcomes Rossetti, Sabrina Coppola, Elisabetta <p><span lang="EN-US">This study provides real-world evidence that homologous recombination repair (HRR) gene mutations, particularly in <em>BRCA2</em>, are associated with more aggressive clinical and pathological features in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Importantly, mutations located in functional domains of <em>BRCA2</em>, such as the DNA-binding domain and exon 11, were linked to worse oncological outcomes. The findings suggest that not all <em>BRCA2</em> mutations carry the same prognostic value. These results support the potential utility of detailed genetic profiling for risk stratification and treatment personalization in mHSPC.</span></p> |
| title | Prostate cancer and homologous recombination repair gene mutations: a monocentric observational study on clinical and histopathological features and their association with oncological outcomes |
| url | https://doi.org/10.5281/zenodo.15189983 |